Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.69 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 14/20 | 0.32 |
| ▸ | PPARA | Q07869 | 5/20 | 0.32 |
| ▸ | PPARG | P37231 | 3/20 | 0.32 |
| ▸ | DHFR | P00374 | 2/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL534038 | 0.91 | PTGDR2 (0.72) | PTGDR2TTRPPARDPPARAPPARG | |
| SCHEMBL13321253 | 0.90 | PTGDR2 (0.71) | PTGDR2TTRPPARDDHFRFFAR1 | |
| SCHEMBL3776129 | 0.90 | PTGDR2 (0.78) | PTGDR2PPARDFFAR1 | |
| SCHEMBL3770942 | 0.89 | PTGDR2 (0.74) | PTGDR2PPARDPPARAPPARGFFAR1 | |
| SCHEMBL2574995 | 0.88 | PTGDR2 (0.69) | PTGDR2PPARDPPARAPPARGFFAR1 | |
| SCHEMBL534188 | 0.88 | PTGDR2 (0.71) | PTGDR2PPARDPPARAPPARGFFAR1 | |
| SCHEMBL534256 | 0.88 | PTGDR2 (0.73) | PTGDR2PPARDFFAR1 | |
| SCHEMBL2574688 | 0.87 | PTGDR2 (0.72) | PTGDR2PPARDPPARAPPARGFFAR1 | |
| SCHEMBL2570543 | 0.87 | PTGDR2 (0.74) | PTGDR2PPARDPPARADHFRFFAR1 | |
| SCHEMBL3772926 | 0.86 | PTGDR2 (0.68) | PTGDR2PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173812-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| US-8173812-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| US-20100144787-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100144787-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144787-A1 | Quinolines and Their Therapeutic Use | CHRM3, CHRM2, HRH1 | PTGDR2 301/4885TTR 3897/4885PPARD 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.